A biophysical approach of tyrphostin AG879 binding information in : bovine serum albumin, human ErbB2, c-RAF1 kinase, SARS-CoV-2 main protease and angiotensin-converting enzyme 2
Viral infections cause significant health problems all over the world, and it is critical to develop treatments for these problems. Antivirals that target viral genome-encoded proteins frequently cause the virus to become more resistant to treatment. Because viruses rely on several cellular proteins and phosphorylation processes that are essential to their life cycle, drugs targeting host-based targets could be a viable treatment option. To reduce costs and improve efficiency, existing kinase inhibitors could be repurposed as antiviral medications; however, this method rarely works, and specific biophysical approaches are required in the field. Because of the widespread use of FDA-approved kinase inhibitors, it is now possible to better understand how host kinases contribute to viral infection. The purpose of this article is to investigate the tyrphostin AG879 (Tyrosine kinase inhibitor) binding information in Bovine Serum Albumin (BSA), human ErbB2 (HER2), C-RAF1 Kinase (c-RAF), SARS-CoV-2 main protease (COVID 19), and Angiotensin-converting enzyme 2 (ACE-2).Communicated by Ramaswamy H. Sarma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of biomolecular structure & dynamics - 42(2024), 3 vom: 27. Feb., Seite 1455-1468 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karthikeyan, Subramani [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.02.2024 Date Revised 15.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/07391102.2023.2204368 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356182312 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356182312 | ||
| 003 | DE-627 | ||
| 005 | 20240215231848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/07391102.2023.2204368 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM356182312 | ||
| 035 | |a (NLM)37114656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karthikeyan, Subramani |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A biophysical approach of tyrphostin AG879 binding information in |b bovine serum albumin, human ErbB2, c-RAF1 kinase, SARS-CoV-2 main protease and angiotensin-converting enzyme 2 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2024 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Viral infections cause significant health problems all over the world, and it is critical to develop treatments for these problems. Antivirals that target viral genome-encoded proteins frequently cause the virus to become more resistant to treatment. Because viruses rely on several cellular proteins and phosphorylation processes that are essential to their life cycle, drugs targeting host-based targets could be a viable treatment option. To reduce costs and improve efficiency, existing kinase inhibitors could be repurposed as antiviral medications; however, this method rarely works, and specific biophysical approaches are required in the field. Because of the widespread use of FDA-approved kinase inhibitors, it is now possible to better understand how host kinases contribute to viral infection. The purpose of this article is to investigate the tyrphostin AG879 (Tyrosine kinase inhibitor) binding information in Bovine Serum Albumin (BSA), human ErbB2 (HER2), C-RAF1 Kinase (c-RAF), SARS-CoV-2 main protease (COVID 19), and Angiotensin-converting enzyme 2 (ACE-2).Communicated by Ramaswamy H. Sarma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 main protease | |
| 650 | 4 | |a angiotensin-converting enzyme 2 | |
| 650 | 4 | |a bovine serum albumin | |
| 650 | 4 | |a c-RAF1 kinase | |
| 650 | 4 | |a human ErbB2 | |
| 650 | 4 | |a tyrphostin AG879 | |
| 650 | 7 | |a AG-879 |2 NLM | |
| 650 | 7 | |a Tyrphostins |2 NLM | |
| 650 | 7 | |a Serum Albumin, Bovine |2 NLM | |
| 650 | 7 | |a 27432CM55Q |2 NLM | |
| 650 | 7 | |a 3C-like proteinase, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a EC 3.4.22.- |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Coronavirus 3C Proteases |2 NLM | |
| 650 | 7 | |a EC 3.4.22.28 |2 NLM | |
| 700 | 1 | |a Sundaramoorthy, Anandh |e verfasserin |4 aut | |
| 700 | 1 | |a Kandasamy, Saravanan |e verfasserin |4 aut | |
| 700 | 1 | |a Bharanidharan, Ganesan |e verfasserin |4 aut | |
| 700 | 1 | |a Aruna, Prakasarao |e verfasserin |4 aut | |
| 700 | 1 | |a Suganya, Ramakrishnamurthy |e verfasserin |4 aut | |
| 700 | 1 | |a Mangaiyarkarasi, Rajendiran |e verfasserin |4 aut | |
| 700 | 1 | |a Ganesan, Singaravelu |e verfasserin |4 aut | |
| 700 | 1 | |a Pandian, Ganesh N |e verfasserin |4 aut | |
| 700 | 1 | |a Ramamoorthi, Anitha |e verfasserin |4 aut | |
| 700 | 1 | |a Chinnathambi, Shanmugavel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biomolecular structure & dynamics |d 1985 |g 42(2024), 3 vom: 27. Feb., Seite 1455-1468 |w (DE-627)NLM012639974 |x 1538-0254 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:3 |g day:27 |g month:02 |g pages:1455-1468 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/07391102.2023.2204368 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 3 |b 27 |c 02 |h 1455-1468 | ||